Abstract:OBJECTIVE:To identify the effect of postoperative adjuvant transarterial chemoembolization (TACE) on late recurrence of hepatocellular carcinoma (HCC) patients after radical resection. METHODS:From year 2001 to 2007, 2436 HCC patients underwent radical resection were retrospectively selected. Patients underwent resection only were classified into control group, while those received adjuvant TACE within 2 months after operation were classified into intervention group. Patients were further stratified into those with tumor5 cm and presenting low or high risk factors for recurrence. Patients with single tumor and without microscopic tumor thrombus were defined as low risk for recurrence; otherwise they were defined as high risk. The effect of adjuvant TACE on late (>2 years) recurrence was evaluated. RESULTS:Recurrence rates of tumor5 cm and presenting low, high risk factors for recurrence at 2-year after resection were 20.38%, 33.06%, 30.54% and 50.82%, respectively in the control group, compared with 25.41%, 39.61%, 40.55% and 51.57%, respectively in the intervention group; there were no significant differences between intervention group and control group in each stratum. For patients recurred or died within the first 2 years after resection, the median survival of tumor>5 cm and presenting high risk factors for recurrence was 24 months in the intervention group and 12 months in the Control group. Only in this subgroup, the survival curve of the intervention group was significantly higher than that compared to the control group. For patients who remained recurrence free and survived within the first 2 years after resection, there were no significant differences in the recurrence curves between the intervention group and control group in each stratum; while cumulative survival rates in the subgroup of patients with tumor size is less than or equal to 5 cm and presenting low risk factors for recurrence were 93.95%, 91.50% and 88.42% respectively in the control group, compared with 91.70%, 81.32% and 78.19% respectively in the intervention group at 3-, 4- and 5-year after resection (P=0.0062); for other subgroups, there were no significant differences in the survival curves between the intervention group and the control group in each stratum. Cox regression model suggested adjuvant TACE was not an independent risk factor for late recurrence; however, it might have negative effect on survival [hazard ratio (HR)=1.50, P=0.062] for those patients (especially patients with tumor is less than or equal to 5 cm and presenting low risk factors for recurrence). CONCLUSIONS:The value of adjuvant TACE was mainly due to its therapeutic actions on residual tumor or early recurrence. It had no effect on postponing or eliminating late recurrence; moreover, it could be a risk rather than a benefit in patients at low risk for recurrence (especially those with tumor is less than or equal to 5 cm and presenting low risk factors for recurrence).

The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification

CT-Based Radiomics for the Recurrence Prediction of Hepatocellular Carcinoma after Surgical Resection

Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization

Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization

Postsurgical Treatment With Adjuvant Transarterial Chemoembolization In Patients With Hepatitis B-Related Hepatocellular Carcinoma A Strobe-Compliant Article

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis

[Effect of Postoperative Transcatheter Arterial Chemoembolization on Hepatocellular Carcinoma Patients with Residual Tumor].

Development and Validation of a Risk Prediction Algorithm for Evaluating the Efficacy of Postoperative Adjuvant TACE Therapy for Hepatocellular Carcinoma

Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma

Adjuvant Transarterial Chemoembolization Timing after Radical Resection is an Independent Prognostic Factor for Patients with Hepatocellular Carcinoma

[Effect of Postoperative Adjuvant Transarterial Chemoembolization on Late Recurrence of Hepatocellular Carcinoma after Radical Resection].

Effect of Preoperative Transcatheter Arterial Chemoembolization on Long-term Survival and Recurrence in Patients with Resectable Huge Hepatocelluar Carcinoma A Multicentre Retrospective Analysis

Postoperative Adjuvant Arterial Chemoembolization Improves Survival of Hepatocellular Carcinoma Patients with Risk Factors for Residual Tumor: a Retrospective Control Study.

Adjuvant Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma after Radical Hepatectomy: a Real World Study.

Adjuvant TACE May Not Improve Recurrence-Free or Overall Survival in HCC Patients with Low Risk of Recurrence after Hepatectomy

The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma after Radical Hepatectomy: a Propensity Score-Matching Study

A New Prognostic Algorithm Predicting HCC Recurrence in Patients With Barcelona Clinic Liver Cancer Stage B Who Received PA-TACE

Adjuvant Transarterial Chemoembolization Does Not Influence Recurrence-free and Overall Survivals for Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma after Curative Resection: a Propensity Score Matching Analysis

Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China

A Systematic Review and Meta-Analysis of Adjuvant Transarterial Chemoembolization after Curative Resection for Patients with Hepatocellular Carcinoma